Showing 20 of 206 recruiting trials for “t-cell-prolymphocytic-leukemia”
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
👨⚕️ Janine Stutterheim, Dr, Princess Maxima Center for Pediatric Oncology in The Netherlands📍 112 sites📅 Started Dec 2022View details ↗
RecruitingNCT05929976 ↗
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
CAV Regimen for R/R Ph- B-ALL
Vaccine Responses in Patients With B Cell Malignancies
👨⚕️ Adrian U Wiestner, M.D., National Heart, Lung, and Blood Institute (NHLBI)📍 1 site📅 Started Sep 2022View details ↗
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
Enrolling by InvitationNCT05509855 ↗
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
RecruitingNCT05334069 ↗
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
👨⚕️ Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company📍 144 sites📅 Started Jul 2022View details ↗
RecruitingNCT04785989 ↗
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
👨⚕️ Christopher Fletcher, MD, School of Medicine and Public Health, University of Wisconsin, Madison📍 1 site📅 Started Jun 2022View details ↗
RecruitingNCT05750706 ↗
Incidence of Invasive Fungal Infections Among Patients With Acute Lymphoblastic Leukemia Ph-negative
👨⚕️ Marianna Criscuolo, Fondazione Policlinico Universitario A. Gemelli, IRCCS📍 1 site📅 Started Jun 2022View details ↗
Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
👨⚕️ John C Reneau, MD, PhD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started May 2022View details ↗
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
👨⚕️ Barbara Eichhorst, MD, Prof., Department I of Internal Medicine, University Hospital Cologne📍 30 sites📅 Started Apr 2022View details ↗
Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Bright Ideas - CIN Feasibility Study
RecruitingNCT05840575 ↗
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →